{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,24]],"date-time":"2026-01-24T14:09:21Z","timestamp":1769263761194,"version":"3.49.0"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2013,3,27]],"date-time":"2013-03-27T00:00:00Z","timestamp":1364342400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clin Drug Investig"],"published-print":{"date-parts":[[2013,5]]},"DOI":"10.1007\/s40261-013-0074-0","type":"journal-article","created":{"date-parts":[[2013,3,26]],"date-time":"2013-03-26T11:13:40Z","timestamp":1364296420000},"page":"325-331","source":"Crossref","is-referenced-by-count":26,"title":["Role of Interleukin-28B Polymorphism as a Predictor of Sustained Virological Response in Patients with Chronic Hepatitis C Treated with Triple Therapy: A Systematic Review and Meta-Analysis"],"prefix":"10.1007","volume":"33","author":[{"given":"Simona","family":"Bota","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ioan","family":"Sporea","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roxana","family":"\u015eirli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adriana Maria","family":"Neghin\u0103","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alina","family":"Popescu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mihnea","family":"Str\u0103in","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2013,3,27]]},"reference":[{"key":"74_CR1","unstructured":"WHO. Global surveillance and control of Hepatitis C. Report of a WHO Consultation organized in collaboration with the Viral Hepatitis Prevention Board, Antwerp, Belgium. J Viral Liver. 1999;6(1):34\u20135."},{"issue":"9286","key":"74_CR2","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1016\/S0140-6736(01)06102-5","volume":"358","author":"MP Manns","year":"2001","unstructured":"Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet. 2001;358(9286):958\u201365.","journal-title":"Lancet"},{"issue":"5","key":"74_CR3","doi-asserted-by":"crossref","first-page":"346","DOI":"10.7326\/0003-4819-140-5-200403020-00010","volume":"140","author":"SJ Hadziyannis","year":"2004","unstructured":"Hadziyannis SJ, Sette H Jr, Morgan TR, et al. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med. 2004;140(5):346\u201355.","journal-title":"Ann Intern Med"},{"issue":"3","key":"74_CR4","first-page":"261","volume":"19","author":"I Sporea","year":"2010","unstructured":"Sporea I, Sirli R, Curescu M, et al. Outcome of antiviral treatment in patients with chronic genotype 1 HCV hepatitis: a retrospective study in 507 patients. J Gastrointestin Liver Dis. 2010;19(3):261\u20134.","journal-title":"J Gastrointestin Liver Dis"},{"issue":"6","key":"74_CR5","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1002\/hep.25892","volume":"56","author":"P Marcellin","year":"2012","unstructured":"Marcellin P, Cheinquer H, Curescu M, et al. High sustained virologic response rates in rapid virologic response patients in the large real-world PROPHESYS cohort confirm results from randomized clinical trials. Hepatology. 2012;56(6):2039\u201350.","journal-title":"Hepatology"},{"issue":"3","key":"74_CR6","first-page":"293","volume":"20","author":"S Bota","year":"2011","unstructured":"Bota S, Sporea I, Popescu A, et al. Response to standard of care antiviral treatment in patients with HCV liver cirrhosis: a systematic review. J Gastrointestin Liver Dis. 2011;20(3):293\u20138.","journal-title":"J Gastrointestin Liver Dis"},{"issue":"11","key":"74_CR7","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1080\/00365520802245395","volume":"43","author":"E Syed","year":"2008","unstructured":"Syed E, Rahbin N, Weiland O, et al. Pegylated interferon and ribavirin combination therapy for chronic hepatitis C virus infection in patients with Child-Pugh A liver cirrhosis. Scand J Gastroenterol. 2008;43(11):1378\u201386.","journal-title":"Scand J Gastroenterol"},{"issue":"10","key":"74_CR8","doi-asserted-by":"crossref","first-page":"2164","DOI":"10.1038\/ajg.2010.294","volume":"105","author":"C Fernandez-Rodriguez","year":"2010","unstructured":"Fernandez-Rodriguez C, Alonso S, Martinez SM, et al. PegInterferon plus ribavirin and sustained virological response in HCV-related cirrhosis: outcomes and factors predicting response. Am J Gastroenterol. 2010;105(10):2164\u201372.","journal-title":"Am J Gastroenterol"},{"key":"74_CR9","doi-asserted-by":"crossref","unstructured":"Rauch A, Kutalik Z, Descombes P, et al. Swiss Hepatitis C Cohort Study; Swiss HIV Cohort Study. Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genome-wide association study. Gastroenterology. 2010;138(4):1338\u201345.","DOI":"10.1053\/j.gastro.2009.12.056"},{"key":"74_CR10","doi-asserted-by":"crossref","unstructured":"Grebely J, Petoumenos K, Hellard M, et al. ATAHC Study Group. Potential role for interleukin-28B genotype in treatment decision-making in recent hepatitis C virus infection. Hepatology. 2010;52(4):1216\u201324.","DOI":"10.1002\/hep.23850"},{"issue":"3","key":"74_CR11","first-page":"163","volume":"11","author":"S Li","year":"2011","unstructured":"Li S, Hu P, Zhang QQ, et al. Single nucleotide polymorphisms of the IL28B and sustained virologic response of patients with chronic hepatitis C to PEG-Interferon\/ ribavirin therapy: a meta-analysis. Hepat Mon. 2011;11(3):163\u201372.","journal-title":"Hepat Mon"},{"issue":"2","key":"74_CR12","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1111\/j.1365-2036.2012.05131.x","volume":"36","author":"Y Chen","year":"2012","unstructured":"Chen Y, Xu HX, Wang LJ, Liu XX, Mahato RI, Zhao YR. Meta-analysis: IL28B polymorphisms predict sustained viral response in HCV patients treated with pegylated interferon-\u03b1 and ribavirin. Aliment Pharmacol Ther. 2012;36(2):91\u2013103.","journal-title":"Aliment Pharmacol Ther"},{"issue":"5","key":"74_CR13","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1038\/nrgastro.2011.49","volume":"8","author":"WP Hofmann","year":"2011","unstructured":"Hofmann WP, Zeuzem S. A new standard of care for the treatment of chronic HCV infection. Nat Rev Gastroenterol Hepatol. 2011;8(5):257\u201364.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"74_CR14","doi-asserted-by":"crossref","unstructured":"McHutchison JG, Manns MP, Muir AJ, et al. PROVE3 Study Team. Telaprevir for previously treated chronic HCV infection. N Engl J Med. 2010; 362(14):1292\u2013330.","DOI":"10.1056\/NEJMoa0908014"},{"issue":"5","key":"74_CR15","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1345\/aph.1P430","volume":"45","author":"LS Smith","year":"2011","unstructured":"Smith LS, Nelson M, Naik S, Woten J. Telaprevir: an NS3\/4A Protease inhibitor for the treatment of chronic hepatitis C. Ann Pharmacother. 2011;45(5):639\u201348.","journal-title":"Ann Pharmacother"},{"key":"74_CR16","doi-asserted-by":"crossref","unstructured":"Poordad F, McCone J Jr, Bacon BR, et al. SPRINT-2 Investigators. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med. 2011;364(13):1195\u2013206.","DOI":"10.1056\/NEJMoa1010494"},{"issue":"2","key":"74_CR17","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1053\/j.gastro.2010.10.046","volume":"140","author":"P Marcellin","year":"2011","unstructured":"Marcellin P, Forns X, Goeser T, et al. Telaprevir is effective given every 8 or 12 hours with ribavirin and peginterferon alfa-2a or -2b to patients with chronic hepatitis C. Gastroenterology. 2011;140(2):459\u201368.","journal-title":"Gastroenterology"},{"issue":"3","key":"74_CR18","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","volume":"7","author":"R DerSimonian","year":"1986","unstructured":"DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7(3):177\u201388.","journal-title":"Control Clin Trials"},{"issue":"7109","key":"74_CR19","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","volume":"315","author":"M Egger","year":"1997","unstructured":"Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315(7109):629\u201334.","journal-title":"BMJ"},{"issue":"1","key":"74_CR20","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1093\/infdis\/jir210","volume":"204","author":"K Chayama","year":"2011","unstructured":"Chayama K, Nelson Hayes C, Abe H. IL28B but not ITPA polymorphism is predictive of response to pegylated interferon, ribavirin and telaprevir triple therapy in patients with genotype 1 hepatitis C. J Infect Dis. 2011;204(1):84\u201393.","journal-title":"J Infect Dis"},{"issue":"3","key":"74_CR21","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1159\/000328327","volume":"55","author":"N Akuta","year":"2012","unstructured":"Akuta N, Suzuki F, Hirakawa M, Kawamura Y, Sezaki H, Suzuki Y, et al. Amino acid substitution in HCV core\/NS5A region and genetic variation near IL28B gene affect treatment efficacy to interferon plus ribavirin combination therapy. Intervirology. 2012;55(3):231\u201341.","journal-title":"Intervirology"},{"issue":"2","key":"74_CR22","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1002\/hep.24058","volume":"53","author":"F Suzuki","year":"2011","unstructured":"Suzuki F, Suzuki Y, Akuta N, et al. Influence of ITPA polymorphisms on decrease of hemoglobin during treatment with pegylated interferon, ribavirin and telaprevir. Hepatology. 2011;53(2):415\u201321.","journal-title":"Hepatology"},{"key":"74_CR23","doi-asserted-by":"crossref","unstructured":"Poordad F, Bronowicki JP, Gordon SC, et al. SPRINT-2 and RESPOND-2 Investigators. Factors that predict response of patients with hepatitis C virus infection to boceprevir. Gastroenterology. 2012;143(3):608\u201318.","DOI":"10.1053\/j.gastro.2012.05.011"},{"issue":"Suppl 1","key":"74_CR24","doi-asserted-by":"crossref","first-page":"S6","DOI":"10.1016\/S0168-8278(11)60015-9","volume":"54","author":"S Pol","year":"2011","unstructured":"Pol S, Aerssens J, Zeuzem S, et al. Similar SVR rates in IL28B CC, CT or TT prior relapser, partial or null-responder patients treated with telaprevir\/peginterferon\/ribavirin: retrospective analysis of the REALIZE study [abstract]. J Hepatol. 2011;54(Suppl 1):S6.","journal-title":"J Hepatol"},{"issue":"Suppl 1","key":"74_CR25","doi-asserted-by":"crossref","first-page":"S542","DOI":"10.1016\/S0168-8278(11)61371-8","volume":"54","author":"IM Jacobson","year":"2011","unstructured":"Jacobson IM, Catlett I, Marcellin P, et al. Telaprevir substantially improved SVR rates across all IL28B genotypes in the ADVANCE trial [abstract]. J Hepatol. 2011;54(Suppl 1):S542.","journal-title":"J Hepatol"},{"issue":"2","key":"74_CR26","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1002\/hep.23690","volume":"52","author":"N Akuta","year":"2010","unstructured":"Akuta N, Suzuki F, Hirakawa M, et al. Amino acid substitution in hepatitis C virus core region and genetic variation near the Interleukin 28B gene predict viral response to telaprevir with peginterferon and ribavirin. Hepatology. 2010;52(2):421\u20139.","journal-title":"Hepatology"},{"issue":"Suppl 2","key":"74_CR27","doi-asserted-by":"crossref","first-page":"S430","DOI":"10.1016\/S0168-8278(12)61106-4","volume":"56","author":"JP Bronowicki","year":"2012","unstructured":"Bronowicki JP, Hezode C, Bengtsson L, et al. 100% SVR in IL28B CC patients treated with 12\u00a0weeks of telaprevir, peginterferon and ribavirin in the PROVE2 trial [abstract]. J Hepatol. 2012;56(Suppl 2):S430.","journal-title":"J Hepatol"},{"key":"74_CR28","doi-asserted-by":"crossref","unstructured":"Bacon BR, Gordon SC, Lawitz E, et al. HCV RESPOND-2 Investigators. Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med. 2011;364(13):1207\u201317.","DOI":"10.1056\/NEJMoa1009482"},{"key":"74_CR29","doi-asserted-by":"crossref","unstructured":"Zeuzem S, Andreone P, Pol S; REALIZE Study Team, et al. Telaprevir for retreatment of HCV infection. N Engl J Med. 2011;364(25):2417\u201328.","DOI":"10.1056\/NEJMoa1013086"},{"key":"74_CR30","doi-asserted-by":"crossref","unstructured":"Jacobson IM, McHutchison JG, Dusheiko G, et al. ADVANCE Study Team. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med. 2011;364(25):2405\u201316.","DOI":"10.1056\/NEJMoa1012912"},{"key":"74_CR31","doi-asserted-by":"crossref","unstructured":"H\u00e9zode C, Forestier N, Dusheiko G, et al. PROVE2 Study Team. Telaprevir and peginterferon with or without ribavirin for chronic HCV infection. N Engl J Med. 2009;360(18):1839\u201350.","DOI":"10.1056\/NEJMoa0807650"},{"issue":"4","key":"74_CR32","doi-asserted-by":"crossref","first-page":"e81","DOI":"10.1111\/j.1365-2893.2010.01372.x","volume":"18","author":"S Mauss","year":"2011","unstructured":"Mauss S, Hueppe D, John C, et al. Estimating the likelihood of sustained virological response in chronic hepatitis C therapy. J Viral Hepat. 2011;18(4):e81\u201390.","journal-title":"J Viral Hepat"},{"issue":"2","key":"74_CR33","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1111\/j.1365-2893.2007.00901.x","volume":"15","author":"KR Reddy","year":"2008","unstructured":"Reddy KR, Govindarajan S, Marcellin P, et al. Hepatic steatosis in chronic hepatitis C: baseline host and viral characteristics and influence on response to therapy with peginterferon alpha-2a plus ribavirin. J Viral Hep. 2008;15(2):129\u201336.","journal-title":"J Viral Hep"},{"issue":"1","key":"74_CR34","doi-asserted-by":"crossref","first-page":"9","DOI":"10.2165\/00044011-200828010-00002","volume":"28","author":"G Yamada","year":"2008","unstructured":"Yamada G, Iino S, Okuno T, et al. Virological response in patients with hepatitis C virus genotype 1b and a high viral load: impact of peginterferon-alpha-2a plus ribavirin dose reductions and host-related factors. Clin Drug Investig. 2008;28(1):9\u201316.","journal-title":"Clin Drug Investig"},{"issue":"1","key":"74_CR35","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.jhep.2010.10.032","volume":"55","author":"MW Fried","year":"2011","unstructured":"Fried MW, Hadziyannis SJ, Shiffman ML, et al. Rapid virological response is the most important predictor of virological response across genotypes in patients with chronic hepatitis C virus infection. J Hepatol. 2011;55(1):69\u201375.","journal-title":"J Hepatol"},{"issue":"7262","key":"74_CR36","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1038\/nature08309","volume":"461","author":"D Ge","year":"2009","unstructured":"Ge D, Fellay J, Thompson AJ, et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature. 2009;461(7262):399\u2013401.","journal-title":"Nature"},{"issue":"12","key":"74_CR37","doi-asserted-by":"crossref","first-page":"975","DOI":"10.5812\/kowsar.1735143X.4202","volume":"11","author":"I Sporea","year":"2011","unstructured":"Sporea I, Popescu A, Curescu M, et al. The correlation of Il28B genotype with sustained virologic response in Romanian patients with chronic hepatitis C. Hepat Mon. 2011;11(12):975\u20139.","journal-title":"Hepat Mon"},{"issue":"Suppl 1","key":"74_CR38","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1111\/j.1478-3231.2010.02389.x","volume":"31","author":"JG McHutchison","year":"2011","unstructured":"McHutchison JG. The role of genetic markers in hepatitis C virus therapy: a major step to individualized care. Liver Int. 2011;31(Suppl 1):29\u201335.","journal-title":"Liver Int"},{"issue":"5","key":"74_CR39","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1053\/j.gastro.2005.01.059","volume":"128","author":"L Chen","year":"2005","unstructured":"Chen L, Borozan I, Feld J, et al. Hepatic gene expression discriminates responders and nonresponders in treatment of chronic hepatitis C viral infection. Gastroenterology. 2005;128(5):1437\u201344.","journal-title":"Gastroenterology"},{"issue":"19","key":"74_CR40","doi-asserted-by":"crossref","first-page":"7034","DOI":"10.1073\/pnas.0707882105","volume":"105","author":"M Sarasin-Filipowicz","year":"2008","unstructured":"Sarasin-Filipowicz M, Oakeley EJ, Duong FH, et al. Interferon signaling and treatment outcome in chronic hepatitis C. Proc Natl Acad Sci U S A. 2008;105(19):7034\u20139.","journal-title":"Proc Natl Acad Sci U S A"}],"container-title":["Clinical Drug Investigation"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-013-0074-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40261-013-0074-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-013-0074-0","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,8]],"date-time":"2024-05-08T00:05:32Z","timestamp":1715126732000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40261-013-0074-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,3,27]]},"references-count":40,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2013,5]]}},"alternative-id":["74"],"URL":"https:\/\/doi.org\/10.1007\/s40261-013-0074-0","relation":{},"ISSN":["1173-2563","1179-1918"],"issn-type":[{"value":"1173-2563","type":"print"},{"value":"1179-1918","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,3,27]]}}}